CMS might reconsider a decision to allow broad Medicare coverage of drug-coated stents because of concerns that the devices can increase risk for blood clots.
According to a CMS spokesperson, the agency might restrict Medicare coverage of drug-coated stents to uses approved by FDA, place some restrictions on coverage or maintain current coverage. Medicare in 2005 paid about $14.7 billion for surgeries to implant drug-coated stents.